Pharmacokinetics and Safety of Inhaled Oxytocin Compared with Intramuscular Oxytocin: The First Randomised Open-Label Study in Women in the Third Stage of Labour
Authors:
- Subramanya KumarSKSubramanya Kumar
- Kirsten R. PalmerKPKirsten R. Palmer
- Anthony CahnACAnthony Cahn
- Rachel A. GibsonRGRachel A. Gibson
- Simon ParrySPSimon Parry
- Annie StylianouASAnnie Stylianou
- Kimberley HacquoilKHKimberley Hacquoil
- Marcy PowellMPMarcy Powell
- Melissa EllisMEMelissa Ellis
Preprint
- 1 January 2021
- preprint
- Published by Elsevier in SSRN Electronic Journal
Abstract
Background: Intramuscular (IM) oxytocin for postpartum haemorrhage (PPH) prevention in resource-poor settings is limited by the need for cold-chain storage and skilled staff for safe injection. We compared the pharmacokinetics (PK) and safety of heat-stable oxytocin inhaled (IH) versus IM administration in women during third stage of labour (TSL). Methods: The phase 1, randomised, open-label clinical study (NCT02999100) was conducted across three centres in the UK and Australia. Participants (Group 1, women in TSL; Group 2, non-pregnant women of childbearing potential) were randomised 1:1 via validated GSK internal software: Group 1, oxytocin 240 IU (400 μg) IH or oxytocin 10 IU (17 μg) IM immediately after delivery; Group 2, intravenous (IV) oxytocin 5 IU (8·5 μg) and oxytocin 240 IU (400 μg) IH at two separate dosing sessions in a cross-over design. Primary endpoints included characterising oxytocin IH PK. The safety population included patients who received ≥1 dose; any PK sample obtained and analysed was included in the PK population. Additional investigations explored the validity of the PK concentration data. Findings: Participants were recruited between November 2016 and March 2019. In Group 1, 29 participants were randomised; 17 received IH (n=9) or IM (n=8) oxytocin. After IH and IM administration most plasma oxytocin concentrations were below quantification limits (2 pg/ml). In Group 2 (n=14), oxytocin IH concentrations remained quantifiable up to 3 hrs post dose. Adverse events were reported for: Group 1, IH n=3 (33%) and IM n=2 (25%); Group 2, n=14 (100%). No deaths were reported. Interpretation: Safety profiles of oxytocin IH and IM were similar; PK profiles could not be defined for oxytocin IH or IM in women in TSL, despite using a highly sensitive assay. Ex vivo investigations suggested oxytocin metabolism occurred in vivo and not during sample collection and processing. Trial Registration: Trial Registration Number, (ClinicalTrials.gov: NCT02999100). The study protocol can be found online (https://clinicaltrials.gov/ProvidedDocs/00/NCT02999100/Prot_000.pdf). Funding: GlaxoSmithKline (GSK 205920; NCT02999100) Declaration of Interest: KG-K, AS-C, KRP, PL, TN, JM, CG, CK and VLO have no conflicts to declare. SK, AC, RAG, SP, IS, AS, KH, MP, ME and SS are employees of and hold stocks in GSK. MPM is an inventor on the patent method and formulation for oxytocin inhalation (WO2013/016754 A1 [PCT/AU2011001430]). Ethical Approval: The study protocol was reviewed and approved by the Office for Research Ethics Committees of Northern Ireland (UK) and the Monash Health Human Research Ethics Committee (Australia) in accordance with Good Clinical Practice (GCP) guidelines.Keywords
This publication has 25 references indexed in Scilit:
- Evaluation of Enzyme Immunoassay and Radioimmunoassay Methods for the Measurement of Plasma OxytocinPsychosomatic Medicine, 2011
- Hemodynamic effects of continuous intravenous injection and bolus plus continuous intravenous injection of oxytocin in cesarean sectionKorean Journal of Anesthesiology, 2011
- Chapter 22 Cardiovascular effects of oxytocin2002
- Amniotic oxytocin and vasopressin in relation to human fetal development and labourEarly Human Development, 1989
- Elevated Plasma Levels Of Oxytocin In Women Taking Low‐Dose Oral Contraceptives: Identification Of The Plasma Oxytocin With High Performance Liquid ChromatographyActa Obstetricia et Gynecologica Scandinavica, 1989
- Plasma oxytocin during third stage of labour: comparison of natural and active management.BMJ, 1988
- Oxytocin levels in maternal and fetal plasma, amniotic fluid, and neonatal plasma and urineArchives of Gynecology and Obstetrics, 1987
- Cystine aminopeptidases from pregnancy serum and placentaBiochemical Medicine, 1978
- THE CIRCULATING LEVELS OF OXYTOCIN FOLLOWING INTRAVENOUS AND INTRAMUSCULAR ADMINISTRATION OF SYNTOMETRINEBJOG: An International Journal of Obstetrics & Gynaecology, 1972
- INACTIVATION OF OXYTOCIN BY PLASMA OF PREGNANT WOMENBJOG: An International Journal of Obstetrics & Gynaecology, 1959